PVLA
Palvella Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +27.3% ·
share flow +30.0% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 494.66K | +202.0% | $31.01M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (passive) | 487.62K | +9.6% | $30.57M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 3 | Point72 Asset Management ✦ | 317.31K | New | $19.89M | 0.0% | New | 1 | SEC ↗ |
| 4 | Goldman Sachs Group ✦ | 236.63K | — | $14.83M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 168.11K | -3.4% | $10.54M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 6 | Morgan Stanley ✦ | 138.50K | — | $8.68M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 7 | State Street Global Advisors ✦ (passive) | 137.25K | +67.4% | $8.60M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Fidelity (FMR) ✦ | 110.45K | +108180.4% | $6.92M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 89.70K | +34.2% | $5.62M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Millennium Management ✦ | 26.87K | -91.5% | $1.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Wellington Management ✦ | 23.70K | New | $1.49M | 0.0% | New | 1 | SEC ↗ ×3 |
| 12 | JPMorgan Chase ✦ | 8.68K | — | $543,898 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 13 | Two Sigma Investments ✦ | 4.09K | New | $256,402 | 0.0% | New | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 3.66K | New | $230,000 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $19.89M | 0.0% |
| Wellington Management | $1.49M | 0.0% |
| Two Sigma Investments | $256,402 | 0.0% |
| T. Rowe Price | $230,000 | 0.0% |
Exited
| Marshall Wace | $1.11M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 181 holders, 13.20M shares, $1.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 989 sh · $150,686
Officer · 1.66K sh · $250,773
Officer · 1.65K sh · $253,465
Director · 560 sh · $84,743
Director · 263 sh · $39,556
Director · 954 sh · $142,507
Director · 1.56K sh · $238,834
Director · 5.63K sh · $853,037
Director · 6.16K sh · $937,034
Director · 1.27K sh · $194,997
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology